Protara Therapeutics, Inc.
TARA
$3.44
-$0.08-2.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.98% | -0.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.07% | 15.66% | |||
| Operating Income | -16.07% | -15.66% | |||
| Income Before Tax | -13.82% | -17.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.82% | -17.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.82% | -17.93% | |||
| EBIT | -16.07% | -15.66% | |||
| EBITDA | -16.20% | -15.77% | |||
| EPS Basic | 3.84% | -12.14% | |||
| Normalized Basic EPS | 3.85% | -12.14% | |||
| EPS Diluted | 3.84% | -12.14% | |||
| Normalized Diluted EPS | 3.85% | -12.14% | |||
| Average Basic Shares Outstanding | 18.37% | 5.16% | |||
| Average Diluted Shares Outstanding | 18.37% | 5.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||